Neutronic performance characteristics of different LEU fuels in a proposed NIST research reactor.

As a potential replacement for the National Bureau Standards Reactor (NBSR) at the U.S. National Institute of Standards and Technology (NIST), a conceptual design of a new reactor with a horizontally-split core has recently been studied using low-enriched uranium (LEU) silicide dispersion (U3Si2/Al) fuel. In this paper, the neutronics calculations of the proposed NIST reactor with other two low-enriched U-Mo fuels (U-10Mo monolithic fuel and U-7Mo/Al dispersion fuel) were performed, and the results were compared to that of the U3Si2/Al fuel, with the objective of identifying the best fuel candidate for the reactor cycle length and maximum cold neutron production. To make consistent comparisons, fuel inventories for multi-cycle equilibrium cores were produced for each fuel based on a 30 d reactor cycle at 20 MW thermal power. With its very high uranium density, the potential to load more uranium in the core with U-10Mo monolithic fuel was explored with test cases using an alternate fuel management scheme, a higher power level (30 MW), or a longer cycle (45 d). The research results indicate similar neutronics performance characteristics of the three LEU fuel options in the proposed NIST reactor with the same power level. However, the ability to load more fuel in the reactor with the U-10Mo option allows additional flexibility in the reactor design and could lead to other optimizations that maximize cold neutron production.

A critical examination of the results from the Harvard-MIT NCT program phase I clinical trial of neutron capture therapy for intracranial disease.

A phase I trial was designed to evaluate normal tissue tolerance to neutron capture therapy (NCT); tumor response was also followed as a secondary endpoint. Between July 1996 and May 1999, 24 subjects were entered into a phase I trial evaluating cranial NCT in subjects with primary or metastatic brain tumors. Two subjects were excluded due to a decline in their performance status and 22 subjects were irradiated at the MIT Nuclear Reactor Laboratory. The median age was 56 years (range 24-78). All subjects had a pathologically confirmed diagnosis of either glioblastoma (20) or melanoma (2) and a Karnofsky of 70 or higher. Neutron irradiation was delivered with a 15 cm diameter epithermal beam. Treatment plans varied from 1 to 3 fields depending upon the size and location of the tumor. The 10B carrier, L-p-boronophenylalanine-fructose (BPA-f), was infused through a central venous catheter at doses of 250 mg kg(-1) over 1 h (10 subjects), 300 mg kg(-1) over 1.5 h (two subjects), or 350 mg kg(-1) over 1.5-2 h (10 subjects). The pharmacokinetic profile of 10B in blood was very reproducible and permitted a predictive model to be developed. Cranial NCT can be delivered at doses high enough to exhibit a clinical response with an acceptable level of toxicity. Acute toxicity was primarily associated with increased intracranial pressure; late pulmonary effects were seen in two subjects. Factors such as average brain dose, tumor volume, and skin, mucosa, and lung dose may have a greater impact on tolerance than peak dose alone. Two subjects exhibited a complete radiographic response and 13 of 17 evaluable subjects had a measurable reduction in enhanced tumor volume following NCT.